Jonathan Young - Jul 15, 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Chief Operating Officer
Signature: /s/ Jonathan Young
Stock symbol: AKRO
Transactions as of: Jul 15, 2021
Transactions value $: $5,535
Form type: 4
Date filed: 7/19/2021, 04:43 PM
Previous filing: Jun 2, 2021
Next filing: Sep 3, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Options Exercise	$5.54K	+9K	+5.49%	$0.62^*	173K	Jul 15, 2021	Direct
holding	AKRO	Common Stock						20K	Jul 15, 2021	By EA Irrevocable Trust	F1
holding	AKRO	Common Stock						20K	Jul 15, 2021	By CM Irrevocable Trust	F1
holding	AKRO	Common Stock						20K	Jul 15, 2021	By JL Irrevocable Trust	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Employee Stock Option (Right to Buy)	Options Exercise	$0	-9K	-25.5%	$0.00	26.3K	Jul 15, 2021	Common Stock	9K	$0.62	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2	25% of this option vested on August 1, 2018 and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.